Today, the Novo Nordisk Foundation announced the € 300 million funding of an international consortium including Leiden University Medical Center, the Danstem Institute at the University of Copenhagen and the Murdoch Childrens Research Institute in Melbourne to bring stem cell-based therapies from the laboratory to the patient.

NecstGen collaborates in this consortium as development and manufacturing partner to help advance cell and gene therapies through clinical development.

During a 10-year period, the consortium will focus on tissue reconstruction, clinical application of stem cells, and genetic modification techniques.